This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Sancuso-product-image

SANCUSO®

granisetron transdermal patch

SANCUSO transdermal patch is indicated for the prevention of nausea and vomiting associated with moderately or highly emetogenic multi-day chemotherapy in adult patients with swallowing difficulties.1

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

Click here for prescribing information.

Efficacy

SANCUSO provides effective control of chemotherapy-induced nausea and vomiting (CINV) associated with moderate emetogenic (MEC) or highly emetogenic (HEC) multi-day chemotherapy.1,2

The efficacy and tolerability of transdermal granisetron for the control of CINV associated with MEC and HEC multi-day chemotherapy was demonstrated via a randomized, double-blind, phase III study (n=641).2

Nearly 80% of patients achieved complete control of daily CINV symptoms throughout the course of their chemotherapy.3 Complete control is defined as:3

  • No vomiting / retching.
  • No more than mild nausea.
  • No need for rescue medication.

The efficacy and safety of SANCUSO is comparable to oral granisetron.4

Average:

  • References

    1. SANCUSO 3.1 mg/24 hours transdermal patch SPC.

    2. Boccia R et al. Support Care Cancer. 2011;19:1609-1617.

    3. SANCUSO European Public Assessment Report EMA/228344/2012.

    4. SANCUSO EPAR Product Information 05/2012.

    KKI/UK/IM-M1/0001 November 2023